(MNTA)—MYL needs to get generic Copaxone (and generic Advair) approved in the US to hit the very aggressive 2018 targets the company has given to investors for sales and EPS. If MYL fails to get these products approved, the shortfall would presumably have to be made up via one or more acquisitions that are accretive to EPS.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.